 The incidence of hepatic decompensations and mortality is reduced considerable in patients who achieve sustained virologic response SVR to therapy against hepatitis C virus HCV infection. With the arrival of direct-acting antivirals AAD against HCV, rates of SVR are significantly higher than what was achieved with pegylated interferon peg-IFN in combination with ribavirin RBV. Therefore, AADs could have a high impact in this context. Therefore, triple therapy against HCV genotype 1 based on the first-generation protease inhibitors PI telaprevir TVR or boceprevir BOC plus peg-IFNRBV became standard therapy in 2011 and SVR rates as high as 68-75 were reached in treatment-naïve patients. In treatment-experienced subjects, retreatment with triple therapy resulted in higher SVR rates than what was observed with dual therapy alone, however, treatment success strongly depends on the previous response pattern. Unfortunately, combinations based on TVR or BOC are not well tolerated, treatments are complex, costs are high and pharmacological interactions are frequently observed. 